Defiance ETFs Launched NVOX, The World's First Single-stock Leveraged ETF For The Pharmaceutical Stock Novo Nordisk
Defiance ETFs Launched NVOX, The World's First Single-stock Leveraged ETF For The Pharmaceutical Stock Novo Nordisk
Defiance etf推出NVOX，世界上第一支專注於藥品股Novo Nordisk的單支股票槓桿etf
As the weight loss market continues to expand and Novo Nordisk is a key provider in that space, NVOX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Novo Nordisk without the need for a margin account.
隨着減肥市場不斷擴大，諾和諾德是該領域的主要供應商，NVOX爲散戶投資者提供了2倍的日常開多槓桿暴露於諾和諾德的每日股價變動，無需按金帳戶。
This provides a unique tool for tactical traders. NVOX does not invest directly in Novo Nordisk and has a higher degree of risk due to tracking a single stock.
這爲戰術交易者提供了獨特的工具。NVOX並不直接投資諾和諾德，並由於跟蹤股票期貨而具有更高的風險。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。